Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Montevialeon Nov 15, 2017 8:38pm
76 Views
Post# 26972728

RE:RE:RE:RE:Aphria Sold their Position in Kalytera

RE:RE:RE:RE:Aphria Sold their Position in Kalyterapp19888....thats exactly my point.  The financial statements everyone is referring to were prepared as of August 31, 2017.   The investor deck is dated October 12, 2017.  Sometime between August 31 and October 12th Aphria may have liquidated their shares in Kalytera.  

The reason I say this is because before October 12 Aphria always showed Kalytera listed on page 3 of the Investor Deck as one of their investments.  It was always listed under Science heading along with Medlab and TBP.  However when they updated the investor deck on October 12th it no longer appears.  They deliberately removed it.  It used to appear in all their previous investor decks.  

Unless someon can point me to more convincing information other than their last financial statement dated August 31, 2017 then the logical conclusion is that they sold their investment and removed it from the list of investments they own in the investor deck.  I wish they still held it, but investor deck tells a different story.  

We know this is going to be a good quarter.  They may be planning to bury the loss in this quarter similar to what they did for Canabo Medical Clinic.  

M

pp19888 wrote: It’s shows fair value of their investment as on aug 2017 when compared to may 2017. Learn how to read the reports.


Bullboard Posts